Entourage Health Past Earnings Performance
Past criteria checks 0/6
Entourage Health's earnings have been declining at an average annual rate of -29.2%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 17.4% per year.
Key information
-29.2%
Earnings growth rate
-18.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 17.4% |
| Return on equity | n/a |
| Net Margin | -103.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Entourage Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 42 | -43 | 23 | 0 |
| 31 Dec 23 | 41 | -46 | 25 | 0 |
| 30 Sep 23 | 39 | -117 | 28 | 0 |
| 30 Jun 23 | 41 | -124 | 29 | 0 |
| 31 Mar 23 | 40 | -124 | 32 | 0 |
| 31 Dec 22 | 41 | -123 | 31 | 0 |
| 30 Sep 22 | 43 | -80 | 30 | 0 |
| 30 Jun 22 | 44 | -80 | 27 | 0 |
| 31 Mar 22 | 44 | -81 | 30 | 0 |
| 31 Dec 21 | 42 | -79 | 30 | 0 |
| 30 Sep 21 | 37 | -80 | 33 | 0 |
| 30 Jun 21 | 32 | -89 | 35 | 0 |
| 31 Mar 21 | 28 | -88 | 30 | 0 |
| 31 Dec 20 | 29 | -90 | 30 | 0 |
| 30 Sep 20 | 27 | -51 | 25 | 0 |
| 30 Jun 20 | 28 | -39 | 23 | 0 |
| 31 Mar 20 | 30 | -17 | 25 | 0 |
| 31 Dec 19 | 21 | -10 | 23 | 0 |
| 30 Sep 19 | 21 | -11 | 24 | 0 |
| 30 Jun 19 | 16 | 12 | 21 | 0 |
| 31 Mar 19 | 10 | -2 | 19 | 0 |
| 31 Dec 18 | 8 | -1 | 15 | 0 |
| 30 Sep 18 | 6 | 5 | 9 | 0 |
| 30 Jun 18 | 4 | -6 | 7 | 0 |
| 31 Mar 18 | 3 | -9 | 7 | 0 |
| 31 Dec 17 | 1 | -9 | 6 | 0 |
| 30 Sep 17 | 1 | -7 | 5 | 0 |
| 30 Jun 17 | 0 | -7 | 4 | 0 |
| 31 Mar 17 | 0 | -3 | 2 | 0 |
| 31 Dec 16 | 0 | -2 | 2 | 0 |
| 30 Sep 16 | 0 | -1 | 2 | 0 |
| 31 Dec 15 | 0 | -3 | 2 | 0 |
Quality Earnings: ETRG.F is currently unprofitable.
Growing Profit Margin: ETRG.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ETRG.F is unprofitable, and losses have increased over the past 5 years at a rate of 29.2% per year.
Accelerating Growth: Unable to compare ETRG.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ETRG.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.9%).
Return on Equity
High ROE: ETRG.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.